These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 23433)

  • 1. Study of the structural requirements for dopa potentiation and oxotremorine antagonism by L-prolyl-L-leucylglycinamide.
    Johnson RL; Smissman EE; Plotnikoff NP
    J Med Chem; 1978 Feb; 21(2):165-9. PubMed ID: 23433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolyl-leucyl-glycine amide (PLG) and thyrotropin-releasing hormone (TRH): DOPA potentiation and biogenic amine studies.
    Plotnikoff NP
    Prog Brain Res; 1975; 42():11-23. PubMed ID: 730
    [No Abstract]   [Full Text] [Related]  

  • 3. Synthetic MIF analogues. Part II: Dopa potentiation and fluphenazine antagonism.
    Voith K
    Arzneimittelforschung; 1977; 27(12):2290-3. PubMed ID: 23795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine receptor modulation by Pro-Leu-Gly-NH2 analogues possessing cyclic amino acid residues at the C-terminal position.
    Johnson RL; Rajakumar G; Mishra RK
    J Med Chem; 1986 Oct; 29(10):2100-4. PubMed ID: 2876103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DOPA potentiation in ablated animals and brain levels of biogenic amines in intact animals after prolyl-leucylglycinamide.
    Plotnikoff NP; Minard FN; Kastin AJ
    Neuroendocrinology; 1974; 14(5):271-9. PubMed ID: 4858836
    [No Abstract]   [Full Text] [Related]  

  • 6. Gonadotropin releasing hormone (GnRH): neuropharmacological studies.
    Plotnikoff NP; White WF; Kastin AJ; Schally AV
    Life Sci; 1975 Dec; 17(11):1685-91. PubMed ID: 1107736
    [No Abstract]   [Full Text] [Related]  

  • 7. Potentiation of apomorphine-induced stereotypies by naloxone and L-prolyl-L-leucyl-glycinamide.
    Quock RM; Lucas TS; Hartl TJ
    Pharmacol Biochem Behav; 1983 Jul; 19(1):49-52. PubMed ID: 6137836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxotremorine antagonism by prolyl-leucyl-glycine-amide administered by different routes and with several anticholinergics.
    Plotnikoff NP; Kastin AJ
    Pharmacol Biochem Behav; 1974 May; 2(3):417-9. PubMed ID: 4837910
    [No Abstract]   [Full Text] [Related]  

  • 9. Potentiation of apomorphine action in rats by l-prolyl-l-leucyl-glycine amide.
    Kostrzewa RM; Kastin AJ; Sobrian SK
    Pharmacol Biochem Behav; 1978 Sep; 9(3):375-8. PubMed ID: 30981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiation by naloxone of the anti-oxotremorine effect of L-DOPA.
    Quock RM; Lucas TS
    Eur J Pharmacol; 1983 Nov; 95(3-4):193-8. PubMed ID: 6653670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tripeptide analogues of melanocyte-stimulating hormone release-inhibiting hormone (Pro-Leu-Gly-NH2) as inhibitors of oxotremorine-induced tremor.
    Björkman S; Castensson S; Sievertsson H
    J Med Chem; 1979 Aug; 22(8):931-5. PubMed ID: 40028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensification of central catecholaminergin and serotonergic processes by the hypothalamic factors MIF and TRF and by angiotensin II.
    Huidobro-Toro JP; Scotti de Carolis A; Longo VG
    Pharmacol Biochem Behav; 1975; 3(2):235-42. PubMed ID: 238221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropharmacological tests with alpha-melanocyte stimulating hormone.
    Plotnikoff NP; Kastin AJ
    Life Sci; 1976 Jun; 18(11):1217-22. PubMed ID: 933712
    [No Abstract]   [Full Text] [Related]  

  • 14. A selective potentiation by naloxone of L-dopa but not atropine suppression of oxotremorine-induced tremor in mice.
    Quock RM; Lucas TS
    J Pharm Pharmacol; 1985 Sep; 37(9):673-4. PubMed ID: 2867196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possible association of increased rat behavioral effects and increased striatal dopamine and norepinephrine levels during the DOPA-potentiation test.
    Spirtes MA; Plotnikoff NP; Kostrzewa RM; Harston CT; Kastin AJ; Christensen CW
    Pharmacol Biochem Behav; 1976; 5(Suppl 1):121-4. PubMed ID: 13411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth hormone release inhibiting hormone: neuropharmacological studies.
    Plotnikoff NP; Kastin AJ; Schally AV
    Pharmacol Biochem Behav; 1974; 2(5):693-6. PubMed ID: 4610595
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacological studies with a tripeptide, prolyl-leucyl glycine amide.
    Plotnikoff NP; Kastin AJ
    Arch Int Pharmacodyn Ther; 1974 Oct; 211(2):211-24. PubMed ID: 4156639
    [No Abstract]   [Full Text] [Related]  

  • 18. Thyrotropin releasing hormone: enhancement of dopa activity by a hypothalamic hormone.
    Plotnikoff NP; Prange AJ; Breese GR; Anderson MS; Wilson IC
    Science; 1972 Oct; 178(4059):417-8. PubMed ID: 4627781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and conformational study of two L-prolyl-L-leucyl-glycinamide analogues with a reduced peptide bond.
    Vander Elst P; Elseviers M; De Cock E; Van Marsenille M; Tourwé D; Van Binst G
    Int J Pept Protein Res; 1986 Jun; 27(6):633-42. PubMed ID: 2875969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-prolyl-L-leucyl-glycinamide analogues--a new class of peptide antihypertensives.
    Rajakumar G; Singh AN; Naas F; Chiu S; Kwan CY; Johnson RL; Mishra RK
    J Hypertens Suppl; 1986 Dec; 4(5):S106-8. PubMed ID: 2883271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.